Fusen Pharmaceutical Company Limited (1652.HK)

Name: Fusen Pharmaceutical Company Limited Financial Statements
Creator: Quarter Results

Healthcare | Drug Manufacturers Specialty Generic

Latest reporting period: 2026-04-07

Latest Quarter

2026-04-07

Revenue

$111M

Net Income

-$23.1M

Operating Margin

-18.1%

Free Cash Flow

$57.4M

Debt / Assets

70.2%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Fusen Pharmaceutical Company Limited (1652.HK).
Income Statement (Quarterly)	2026-04-07	2025-06-30	2025-03-31	2024-12-31
Revenue	111,286,000	111,286,000	55,643,000	64,853,500
Cost of Revenue	68,296,000	68,296,000	34,148,000	36,471,000
Gross Profit	42,990,000	42,990,000	21,495,000	28,382,500
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	45,331,000	45,331,000	22,665,500	26,425,500
Operating Expenses	63,184,000	63,184,000	31,592,000	43,868,500
Operating Income	-20,194,000	-20,194,000	-10,097,000	-15,486,000
Interest Expense	0	7,816,000	0	0
Income Before Tax	-22,725,000	-22,725,000	-11,362,500	-72,560,500
Income Tax Expense	411,000	411,000	205,500	3,365,000
Net Income	-23,136,000	-23,136,000	-11,568,000	-75,921,000
Per Share
EPS	-0.03	-0.03	-0.02	-0.10
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Fusen Pharmaceutical Company Limited (1652.HK).
Income Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Revenue	326,029,000	565,608,000	491,757,000	385,664,000	486,854,000
Cost of Revenue	163,392,000	266,102,000	266,736,000	174,531,000	220,787,000
Gross Profit	162,637,000	299,506,000	225,021,000	211,133,000	266,067,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	141,283,000	214,439,000	188,642,000	156,181,000	186,281,000
Operating Expenses	230,148,000	279,490,000	186,414,000	146,646,000	181,830,000
Operating Income	-67,511,000	20,016,000	15,738,000	52,137,000	84,237,000
Interest Expense	18,838,000	12,583,000	12,382,000	9,655,000	9,434,000
Income Before Tax	-190,446,000	-29,448,000	-30,993,000	23,791,000	78,405,000
Income Tax Expense	-1,646,000	6,847,000	3,661,000	7,178,000	15,737,000
Net Income	-188,783,000	-36,277,000	-34,654,000	16,645,000	70,131,000
Per Share
EPS	-0.26	-0.05	-0.05	0.02	0.09
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Fusen Pharmaceutical Company Limited (1652.HK).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	21,056,000	34,849,000	128,106,000	81,063,000
Short Term Investments	0	0	4,595,000	642,000
Net Receivables	113,878,000	183,482,000	247,189,000	0
Inventory	137,082,000	184,199,000	110,649,000	121,845,000
Total Current Assets	459,612,000	566,802,000	614,056,000	509,222,000
Property Plant Equipment	621,330,000	562,182,000	314,370,000	506,034,000
Goodwill and Intangibles	28,135,000	22,551,000	215,858,000	0
Total Assets	1,238,161,000	1,343,745,000	1,350,268,000	1,239,336,000
Liabilities
Account Payables	123,466,000	167,545,000	163,613,000	102,115,000
Short Term Debt	304,464,000	237,643,000	227,949,000	162,748,000
Total Current Liabilities	772,445,000	664,520,000	722,082,000	489,266,000
Long Term Debt	79,230,000	106,472,000	432,000	77,940,000
Total Liabilities	869,799,000	781,519,000	737,375,000	582,392,000
Shareholders Equity
Retained Earnings	0	292,607,000	274,813,000	0
Total Shareholders Equity	369,671,000	563,518,000	614,167,000	658,169,000

Balance sheet annual history for Fusen Pharmaceutical Company Limited (1652.HK).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets
Cash and Cash Equivalents	21,056,000	34,849,000	128,106,000	81,063,000	297,038,000
Short Term Investments	0	0	4,595,000	642,000	15,489,000
Net Receivables	113,878,000	183,482,000	247,189,000	0	0
Inventory	137,082,000	184,199,000	110,649,000	121,845,000	105,415,000
Total Current Assets	459,612,000	566,802,000	614,056,000	509,222,000	660,367,000
Property Plant Equipment	621,330,000	562,182,000	314,370,000	506,034,000	238,002,000
Goodwill and Intangibles	28,135,000	22,551,000	215,858,000	0	248,809,000
Total Assets	1,238,161,000	1,343,745,000	1,350,268,000	1,239,336,000	1,241,347,000
Liabilities
Account Payables	123,466,000	167,545,000	163,613,000	102,115,000	108,585,000
Short Term Debt	304,464,000	237,643,000	227,949,000	162,748,000	178,500,000
Total Current Liabilities	772,445,000	664,520,000	722,082,000	489,266,000	547,606,000
Long Term Debt	79,230,000	106,472,000	432,000	77,940,000	20,000,000
Total Liabilities	869,799,000	781,519,000	737,375,000	582,392,000	583,098,000
Shareholders Equity
Retained Earnings	0	292,607,000	274,813,000	0	0
Total Shareholders Equity	369,671,000	563,518,000	614,167,000	658,169,000	658,249,000

Cash flow quarterly history for Fusen Pharmaceutical Company Limited (1652.HK).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-190,446,000	-29,448,000	-30,993,000	16,645,000
Depreciation & Amortization	41,711,000	35,798,000	34,161,000	23,785,000
Stock Based Compensation	805,000	1,453,000	1,153,000	0
Change in Working Capital	150,503,000	-80,489,000	38,407,000	-30,591,000
Operating Cash Flow	133,730,000	-73,334,000	110,490,000	47,766,000
Investing Activities
Capital Expenditure	-76,298,000	-88,511,000	-23,862,000	-110,133,000
Investments	-60,959,000	-66,241,000	-23,862,000	-110,133,000
Investing Cash Flow	-163,423,000	-108,318,000	-13,131,000	-282,977,000
Financing Activities
Debt Repayment	41,663,000	119,730,000	-306,527,000	-245,569,000
Common Stock Issued/Repurchased	-6,464,000	-15,988,000	-10,073,000	-7,390,000
Dividends Paid	0	0	-6,959,000	-8,306,000
Financing Cash Flow	15,994,000	88,503,000	-51,766,000	20,527,000
Summary
Free Cash Flow	57,432,000	-161,845,000	86,628,000	-62,367,000
Net Change in Cash	-13,793,000	-93,257,000	47,043,000	-215,975,000

Cash flow annual history for Fusen Pharmaceutical Company Limited (1652.HK).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Operating Activities
Net Income	-190,446,000	-29,448,000	-30,993,000	16,645,000	70,131,000
Depreciation & Amortization	41,711,000	35,798,000	34,161,000	23,785,000	22,457,000
Stock Based Compensation	805,000	1,453,000	1,153,000	0	17,632,000
Change in Working Capital	150,503,000	-80,489,000	38,407,000	-30,591,000	44,243,000
Operating Cash Flow	133,730,000	-73,334,000	110,490,000	47,766,000	153,207,000
Investing Activities
Capital Expenditure	-76,298,000	-88,511,000	-23,862,000	-110,133,000	-58,645,000
Investments	-60,959,000	-66,241,000	-23,862,000	-110,133,000	-58,645,000
Investing Cash Flow	-163,423,000	-108,318,000	-13,131,000	-282,977,000	-68,197,000
Financing Activities
Debt Repayment	41,663,000	119,730,000	-306,527,000	-245,569,000	-220,000,000
Common Stock Issued/Repurchased	-6,464,000	-15,988,000	-10,073,000	-7,390,000	-94,793,000
Dividends Paid	0	0	-6,959,000	-8,306,000	-3,145,000
Financing Cash Flow	15,994,000	88,503,000	-51,766,000	20,527,000	-116,330,000
Summary
Free Cash Flow	57,432,000	-161,845,000	86,628,000	-62,367,000	94,562,000
Net Change in Cash	-13,793,000	-93,257,000	47,043,000	-215,975,000	-34,006,000